
Essy Mozaffari, Pharmd, MPH, MBA Joins Emax Health As Head Of Real-World Evidence
Dr. Mozaffari strengthens the eMAX Health senior leadership team with a distinguished background, having held senior roles at Gilead Sciences, Intercept Pharmaceuticals, Chimerix, Sanofi , and Pfizer . A proven innovator in U.S. and global value-evidence development, he will help drive growth in the company's real-world evidence (RWE) business by harnessing eMAX Health's technology-enabled Evidence, Access, and Reimbursement platform.
“Through the global expansion of our proprietary EMRClaims+ RWE asset, a greater on-the-ground presence in key markets, and the launch of eMAX Health's new digital MSL platform , we have a unique opportunity to deliver meaningful service value to the pharmaceutical industry-and, most importantly, to patients,” said Dr. Mozaffari.
“Essy's appointment marks a pivotal milestone as we witness rapid transformation in global pharmaceutical pricing and accelerating adoption of tech-enabled RWE to inform access and regulatory decisions,” said Julian Casciano , Founder and CEO of eMAX Health.“Expanding our global RWE footprint with proprietary assets is a cornerstone of our organic growth strategy. Adding top-tier talent like Dr. Mozaffari is a prime example of how we are leveraging our Fengate partnership completed earlier this year to scale our global RWE capabilities.”
In his new role, Dr. Mozaffari will lead the strategy and execution of RWE programs that support product differentiation, inform payer and regulatory decisions, and strengthen the value narratives of biopharmaceutical clients.
Dr. Mozaffari holds a Doctor of Pharmacy from the University of California, San Francisco , a Master of Public Health from the University of Washington , and an MBA from Rutgers University .
About eMAX Health:
Founded in 2004 by Julian Casciano , eMAX Health is a leader in real-world evidence development , market access , and patient services . The company provides advanced data management and technology-enabled solutions-including proprietary platforms such as MAVA , EMRClaims+ , and HealthPACER -to support pharmaceutical commercialization and improve patient outcomes.
A photo accompanying this announcement is available at
CONTACT: For media inquiries, please contact: Dale Gago Communications and Marketing Business Partner Fengate Asset Management 437 326 1473 ...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- BTCC Exchange Announces Triple Global Workforce Expansion At TOKEN2049 Singapore To Power Web3 Evolution
- Bydfi Joins Korea Blockchain Week 2025 (KBW2025): Deepening Web3 Engagement
- SPAYZ.Io White Paper Explores Opportunities, Challenges And Ambitions In Payments Industry
- Currency Relaunches Under New Leadership, Highlights 2025 Achievements
- Salvium Solves The Privacy Paradox: Salvium One Delivers Mica-Compliant Privacy That Exchanges Can List
- FLOKI Funds Clean Water Wells In Africa Through Partnership With WWFA
Comments
No comment